Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in Splenic Marginal Zone Lymphoma

Table 2

Efficiency of different mitogens and karyotypes in 18 patients with SMZL.

Patient	Age	Sample (*)	Score (**)									Karyotype
			TPA			LPS			ODN + IL2
			Quality	Proliferation	Efficiency	Quality	Proliferation	Efficiency	Quality	Proliferation	Efficiency
1	70	Pb (21.9)	3	3	N	3	2	N	3	3	N	46, XY [20]
2	78	BM (38%)	2	3	N	2	3	A	3	3	A	47, XX, +12 [2]/46,XX [18]
3	77	Pb (7.28)	0	1	F	1	3	A	3	3	A	47, XY, add(5)(p15),+22 [15]/47, XY, add (5)(p15), del (7)(q22),; i(8)(p10), +del (14)(q24) [5]
4	75	BM (35%)	3	3	N	3	4	A	3	2	A	Near tetraploid: 91, XXY, idic (1)(p11), del (11)(q21),; add(14)(q32), +mar1, +mar2 [3]/46, XY [17]
5	76	Pb (8.63)	0	1	F	0	1	F	2	3	A	46, XY, der (3)(p26), del (7)(q32), del (13)(q22) [4]/46, XY [21]
6	69	Pb (34.8)	0	1	F	3	3	N	3	3	N	46, XY [20]
7	55	Pb (16.1)	3	3	N	3	2	A	3	3	A	46, XY, t(3;13)(q21;q13), del (11)(q12) [13]/46, XY [7]
8	84	Pb (20)	0	1	F	3	3	A	4	3	A	46, XX, -9, t(14;19)(q32;q13), +add (14)(q32) [19]/46, XX [1]
9	76	Pb (4.5)	3	3	A	3	3	A	4	4	A	47, XY, +12 [15]/46, XY [5]
10	63	Pb (NA)	2	4	N	2	3	N	2	4	N	46, XY [20]
11	86	Pb (6.1)	3	3	A	1	2	A	3	3	A	46,XX,del(14) (q22) [16]/46,XX [5]
12	76	Spleen	0	1	F	0	1	F	2	3	N	46, XX [20]
13	75	Pb (23.1)	3	3	N	1	2	N	3	4	A	48, XY, +12, +15 [5]/46, XY [15]
14	83	BM (30%)	2	3	N	2	3	N	2	4	A	46, XY, del (3)(p13) [3]/46, XY [17]
15	85	Pb (4.2)	0	1	F	3	3	A	3	3	A	47, XY, +12, del (14)(q24) [12]/46, XY [8]
16	72	Pb (2.9)	0	1	F	0	1	F	4	3	A	46, XY, dup (1)(q21q32), del (7)(q32), del (13)(q14q22) [2]/47, XY, del (7)(q32), der (12) t(3;12)(p11;p11),
												del (13)(q14q22), +mar1 +mar2 [1]/46, XY [17]
17	56	Pb (4.9)	3	3	A	3	4	A	3	3	A	46, XY, del (7)(q32) [8]/46, XY [12]
18	82	Pb (7.1)	3	2	N	0	1	F	3	3	A	47, XX, +3 [4]/46, XX [16]

*Absolute lymphocyte count × 10⁹/L at the time of cytogenetic investigation, or % BM infiltration, as appropriate. NA: not available.
**See materials and methods for details; A: abnormal, N: normal, and F: failure.